One female patient with cancer pain due to bone metastasis from breast cancer was initially treated with Xinhuang tablets, diclofenac sodium double-release enteric-soluble capsules, paracetamol dihydrocodeine tablets and paracetamol oxycodone tablets, before being switched to controlled-release oxycodone hydrochloride tablets. She regularly took oxycodone hydrochloride sustained-release tablets 20 mg, q12h, no abnormalities were observed, and the dosage was increased to 40 mg, q12h due to poor pain control. The patient was diagnosed with 5-hydroxytryptamine syndrome after 1 d of intermittent recurrent tremor, myotonia, scalp sweating, restlessness and elevated blood pressure. When oxycodone hydrochloride sustained release tablet was adjusted to 20 mg, q12h and gabapentin capsule was added to 0.1 g, tid, the frequency of tremor and myotonia attacks slightly decreased, and sweating and agitation symptoms were not relieved. After 14 days, oxycodone hydrochloride sustained release tablets were stopped and morphine sulfate sustained release tablets 60 mg, q12h were replaced. Three days later, the patient's symptoms disappeared. During 5-month follow-up, the patient's pain was well-contrdled, with no change in the dose of morphine sulfate sustained-release tablets, and no adverse drug reactions observed. Using the Naranjo’s Assessment Scale, the association between the patient's serotonin syndrome and the suspected drug oxycodone hydrochloride sustained-release tablets was evaluated as "probable". This case highlights the importance for clinicians to closely monitor adverse reactions induced by rapid opioid dose escalation to ensure medication safety in patients.

1.Khan A, Lahmar A, Asif H, et al. Serotonin syndrome precipitated by the use of cocaine and fentanyl[J]. Cureus. 2022, 14(3): e22805. DOI: 10.7759/cureus.22805.

2.Hölle T, Purrucker JC, Morath B, et al. Zentrales anticholinerges, malignes neuroleptisches und serotoninsyndrom: wichtige differenzialdiagnosen bei postoperativen bewusstseinsstörungen [Central anticholinergic, neuroleptic malignant and serotonin syndromes: important differential diagnoses in postoperative impairment of consciousness][J]. Anaesthesiologie. 2023, 72(3): 157-165. DOI: 10.1007/s00101-023-01256-6.

3.Manjhi PK, Singh MP, Kumar M. Causality, severity, preventability and predictability assessments scales for adverse drug reactions: a review[J]. Cureus, 2024, 16(5): e59975. DOI: 10.7759/cureus.59975.

4.Badar A. Serotonin syndrome: an often-neglected medical emergency[J]. J Family Community Med, 2024, 31(1): 1-8. DOI: 10.4103/jfcm.jfcm_236_23.

5.Kanova M, Kohout P. Serotonin-its synthesis and roles in the healthy and the critically ill[J]. Int J Mol Sci, 2021, 22(9): 4837. DOI: 10.3390/ijms22094837.

6.Poian LR, Chiavegatto S. Serotonin Syndrome: the role of pharmacology in understanding its occurrence[J]. Cureus, 2023, 15(5): e38897. DOI: 10.7759/cureus.38897.

7.Milosavljevic F, Bukvic N, Pavlovic Z, et al. Association of CYP2C19 and CYP2D6 poor and intermediate metabolizer status with antidepressant and antipsychotic exposure: a systematic review and Meta-analysis[J]. JAMA Psychiatry, 2021, 78(3): 270-280. DOI: 10.1001/jamapsychiatry.2020.3643.

8.Hulskotte LMG, Töpfer W, Reyners AKL, et al. Drug-drug interaction perpetrators of oxycodone in patients with cancer: frequency and clinical relevance[J]. Eur J Clin Pharmacol, 2024, 80(3): 455-464. DOI: 10.1007/s00228-023-03612-2.

9.Rickli A, Liakoni E, Hoener MC, et al. Opioid-induced inhibition of the human 5-HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome[J]. Br J Pharmacol. 2018, 175(3): 532-543. DOI: 10.1111/bph.14105.

10.曹宇, 郑策, 杨媛. 氨酚羟考酮片致抽搐等新的不良反应2例[J]. 中国医院药学杂志, 2016, 36(9): 785. [Cao Y, Zheng C, Yang Y. 2 cases of new adverse reactions such as convulsions caused by oxycodone tablets[J]. Chinese Journal of Hospital Pharmacy, 2016, 36(9): 785-785.] DOI: 10.13286/j.cnki.chinhosppharmacyj.2016.09.21.

11.Umukoro NN, Aruldhas BW, Rossos R, et al. Pharmacogenomics of oxycodone: a narrative literature review[J]. Pharmacogenomics, 2021, 22(5): 275-290. DOI: 10.2217/pgs-2020-0143.

12.Petroianu GA. Hyperthermia and serotonin: the quest for a "better cyproheptadine"[J]. Int J Mol Sci, 2022, 23(6): 3365. DOI: 10.3390/ijms23063365.

13.Prakash S, Patel H, Kumar S, et al. Cyproheptadine in serotonin syndrome: a retrospective study[J]. J Family Med Prim Care, 2024, 13(4): 1340-1346. DOI: 10.4103/jfmpc.jfmpc_652_23.

14.Nisijima K, Yoshino T, Yui K, et al. Potent serotonin (5-HT2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome[J]. Brain Res, 2001, 890(1): 23-31. DOI: 10.1016/s0006-8993(00)03020-1.

15.Krishnamoorthy S, Ma Z, Zhang G, et al. Involvement of (5-HT2A) receptors in the serotonin (5-HT) syndrome caused by excessive 5-HT efflux in rat brain[J]. Basic Clin Pharmacol Toxicol, 2010, 107(4): 830-841. DOI: 10.1111/j.1742-7843.2010.00586.x.

16.吴军, 尹长森, 汤其强. 国内41例5-羟色胺综合征文献报告回顾性分析研究[J]. 中风与神经疾病杂志, 2021, 38(6): 526-529. [Wu J, Yin CS, Tang QQ. Clinical features of serotonin syndrome in China: a retrospective analysis of 41 case reports[J]. Journal of Apoplexy and Nervous Diseases, 2021, 38(6): 526-529.] DOI: 10.19845/j.cnki.zfysjjbzz.2021.0140.

17.Elli C, Novella A, Pasina L. Serotonin syndrome: a pharmacovigilance comparative study of drugs affecting serotonin levels[J]. Eur J Clin Pharmacol, 2024, 80(2): 231-237. DOI: 10.1007/s00228-023-03596-z.